Q-TWiST analysis of lapatinib combined with capecitabine for the treatment of metastatic breast cancer

The addition of lapatinib (Tykerb/Tyverb) to capecitabine (Xeloda) delays disease progression more effectively than capecitabine monotherapy in women with previously treated HER2+ metastatic breast cancer (MBC). The quality-adjusted time without symptoms of disease or toxicity of treatment (Q-TWiST)...

Descripción completa

Detalles Bibliográficos
Autores principales: Sherrill, B, Amonkar, M M, Stein, S, Walker, M, Geyer, C, Cameron, D
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2008
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2528149/
https://www.ncbi.nlm.nih.gov/pubmed/18728660
http://dx.doi.org/10.1038/sj.bjc.6604501

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2528149/
https://www.ncbi.nlm.nih.gov/pubmed/18728660
http://dx.doi.org/10.1038/sj.bjc.6604501

Ejemplares similares